Kim Schønnemann Bøttkjær

Managing Partner at FIH Partners A/S

Kim Schønnemann Bøttkjær

Kim Schønnemann Bøttkjær

Managing Partner at FIH Partners A/S

Biography

Mr. Kim S. Bøttkjær is Managing Partner at FIH Partners A/S and Chairman at Glycom A/S. Mr. Bøttkjær also served on the board at Valderm ApS.

Overview
Career Highlights

FIH Partners A/S
Finansieringsinstituttet for Industri og Handvaerk

RelSci Relationships

47

Number of Boards

2

Relationships
RelSci Relationships are individuals Kim Schønnemann Bøttkjær likely has professional access to. A relationship does not necessarily indicate a personal connection.

Partner at FIH Partners A/S

Relationship likelihood: Strong

Partner at FIH Partners A/S

Relationship likelihood: Strong

Partner at FIH Partners A/S

Relationship likelihood: Strong

Managing Partner at Finansieringsinstituttet for Industri og Handvaerk

Relationship likelihood: Strong

Partner at Finansieringsinstituttet for Industri og Handvaerk

Relationship likelihood: Strong

Director at Finansieringsinstituttet for Industri og Handvaerk

Relationship likelihood: Strong

Former Head-Research & Development at Nestlé Nutrition

Relationship likelihood: Strong

Portfolio Manager at Acesion Pharma ApS

Relationship likelihood: Strong

Co-Founder at Glycom A/S

Relationship likelihood: Strong

Professor at University of Hamburg

Relationship likelihood: Strong

Paths to Kim Schønnemann Bøttkjær
Potential Connections via
Relationship Science
You
Kim Schønnemann Bøttkjær
Managing Partner at FIH Partners A/S
Career History
Managing Partner
2006 - Current
Boards & Committees
Chairman
Current

Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark Von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark.

Director
Prior

Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Kim Schønnemann Bøttkjær. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Kim Schønnemann Bøttkjær's profile does not indicate a business or promotional relationship of any kind between RelSci and Kim Schønnemann Bøttkjær.